Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China
Longer survival achieved with fewer severe treatment-related side effects versus comparator...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


